Cochrane · systematic review · CD008295
Felbamate add‐on therapy for drug‐resistant focal epilepsy
Shi, LL, Bresnahan, R, Martin-McGill, KJ, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 5 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsAdd‐on felbamate compared to placebo for drug‐resistant focal epilepsy
Population: people with drug‐resistant focal epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
50% or greater reduction in seizure frequency Add‐on felbamate vs placebo | no estimate extracted | 1 study · 83 participants | Very low Downgraded: risk of bias, imprecision |
Absolute or percentage reduction in seizure frequency Add‐on felbamate vs placebo | no estimate extracted | 3 studies · 172 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Treatment withdrawal Add‐on felbamate vs placebo | no estimate extracted | 4 studies · 236 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Adverse effects Add‐on felbamate vs placebo | no estimate extracted | 4 studies · 236 participants | Very low Downgraded: risk of bias, imprecision |
Quality of life Add‐on felbamate vs placebo | no estimate extracted | 1 study · 64 participants | Very low Downgraded: risk of bias, imprecision |